These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22010965)

  • 1. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.
    Chanan-Khan AA; Chitta K; Ersing N; Paulus A; Masood A; Sher T; Swaika A; Wallace PK; Mashtare TL; Wilding G; Lee K; Czuczman MS; Borrello I; Bangia N
    Br J Haematol; 2011 Nov; 155(4):457-67. PubMed ID: 22010965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
    Aue G; Njuguna N; Tian X; Soto S; Hughes T; Vire B; Keyvanfar K; Gibellini F; Valdez J; Boss C; Samsel L; McCoy JP; Wilson WH; Pittaluga S; Wiestner A
    Haematologica; 2009 Sep; 94(9):1266-73. PubMed ID: 19734418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
    Lapalombella R; Andritsos L; Liu Q; May SE; Browning R; Pham LV; Blum KA; Blum W; Ramanunni A; Raymond CA; Smith LL; Lehman A; Mo X; Jarjoura D; Chen CS; Ford R; Rader C; Muthusamy N; Johnson AJ; Byrd JC
    Blood; 2010 Apr; 115(13):2619-29. PubMed ID: 19965642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.
    Acebes-Huerta A; Huergo-Zapico L; Gonzalez-Rodriguez AP; Fernandez-Guizan A; Payer AR; López-Soto A; Gonzalez S
    Biomed Res Int; 2014; 2014():265840. PubMed ID: 25313353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
    Lapalombella R; Gowda A; Joshi T; Mehter N; Cheney C; Lehman A; Chen CS; Johnson AJ; Caligiuri MA; Tridandapani S; Muthusamy N; Byrd JC
    Br J Haematol; 2009 Mar; 144(6):848-55. PubMed ID: 19183192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
    Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
    Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
    Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
    Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.
    Lee BN; Gao H; Cohen EN; Badoux X; Wierda WG; Estrov Z; Faderl SH; Keating MJ; Ferrajoli A; Reuben JM
    Cancer; 2011 Sep; 117(17):3999-4008. PubMed ID: 21858802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
    Andritsos LA; Johnson AJ; Lozanski G; Blum W; Kefauver C; Awan F; Smith LL; Lapalombella R; May SE; Raymond CA; Wang DS; Knight RD; Ruppert AS; Lehman A; Jarjoura D; Chen CS; Byrd JC
    J Clin Oncol; 2008 May; 26(15):2519-25. PubMed ID: 18427150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
    Maffei R; Fiorcari S; Martinelli S; Benatti S; Bulgarelli J; Rizzotto L; Debbia G; Santachiara R; Rigolin GM; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
    Leuk Lymphoma; 2018 Feb; 59(2):423-433. PubMed ID: 28639485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.
    Biagi E; Dotti G; Yvon E; Lee E; Pule M; Vigouroux S; Gottschalk S; Popat U; Rousseau R; Brenner M
    Blood; 2005 Mar; 105(6):2436-42. PubMed ID: 15536147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.
    Herman SE; Lapalombella R; Gordon AL; Ramanunni A; Blum KA; Jones J; Zhang X; Lannutti BJ; Puri KD; Muthusamy N; Byrd JC; Johnson AJ
    Blood; 2011 Apr; 117(16):4323-7. PubMed ID: 21378270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide and chronic lymphocytic leukemia.
    González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
    Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.
    Masood A; Chitta K; Paulus A; Khan AN; Sher T; Ersing N; Miller KC; Manfredi D; Ailawadhi S; Borrelo I; Lee KP; Chanan-Khan A
    Br J Haematol; 2012 Apr; 157(1):59-66. PubMed ID: 22171982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
    Maffei R; Colaci E; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
    Crit Rev Oncol Hematol; 2016 Jan; 97():291-302. PubMed ID: 26454471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia.
    Rezvany MR; Jeddi-Tehrani M; Rabbani H; Lewin N; Avila-Cariño J; Osterborg A; Wigzell H; Mellstedt H
    Br J Haematol; 2000 Nov; 111(2):608-17. PubMed ID: 11122109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.
    Romano C; De Fanis U; Sellitto A; Dalla Mora L; Chiurazzi F; Giunta R; Rotoli B; Lucivero G
    Leuk Lymphoma; 2003 Nov; 44(11):1963-71. PubMed ID: 14738151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
    Chanan-Khan A; Miller KC; Lawrence D; Padmanabhan S; Miller A; Hernandez-Illatazurri F; Czuczman MS; Wallace PK; Zeldis JB; Lee K
    Cancer; 2011 May; 117(10):2127-35. PubMed ID: 21523725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia.
    Villa-Álvarez M; Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; Payer AR; Gonzalez-Garcia E; Villa-Álvarez MC; López-Soto A; Gonzalez S
    Front Immunol; 2018; 9():2917. PubMed ID: 30619281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.
    Schulz A; Dürr C; Zenz T; Döhner H; Stilgenbauer S; Lichter P; Seiffert M
    Blood; 2013 Mar; 121(13):2503-11. PubMed ID: 23349394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.